These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11717992)

  • 1. [Study on the in vitro and in vivo thrombolytic efficacy of bispecific antifibrin-antiurokinase monoclonal antibodies].
    Yuan H; Lin H; Zhu X; Zhang Y; Zhang X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):357-60. PubMed ID: 11717992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation.
    Ruef J; Nordt TK; Peter K; Runge MS; Kübler W; Bode C
    Thromb Haemost; 1999 Jul; 82(1):109-14. PubMed ID: 10456463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
    Kurokawa T; Iwasa S; Kakinuma A
    Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and characterization of a chimeric bispecific antibody against fibrin and against urokinase-type plasminogen activator.
    Tada H; Kurokawa T; Seita T; Watanabe T; Iwasa S
    J Biotechnol; 1994 Mar; 33(2):157-74. PubMed ID: 7764730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 7. Hybrid molecules: insights into plasminogen activator function.
    Runge MS; Bode C; Haber E; Quertermous T
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
    Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
    Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibody mediated thrombolysis. A new therapeutic principle].
    Bode C; Kübler W
    Klin Wochenschr; 1989 Jul; 67(13):651-8. PubMed ID: 2502649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
    Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
    Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies against urokinase.
    Hérion P; Glineur C; Franssen JD; Urbain J; Bollen A
    Biosci Rep; 1981 Nov; 1(11):885-92. PubMed ID: 7030431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.
    Charpie JR; Runge MS; Matsueda GR; Haber E
    Biochemistry; 1990 Jul; 29(27):6374-8. PubMed ID: 1698452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of monoclonal antifibrin antibodies by their binding to human blood clots.
    Liau CS; Haber E; Matsueda GR
    Thromb Haemost; 1987 Feb; 57(1):49-54. PubMed ID: 3590080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.
    Bos R; Nieuwenhuizen W
    Biotherapy; 1992; 5(3):187-99. PubMed ID: 1419466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-directed urokinase: a specific fibrinolytic agent.
    Bode C; Matsueda GR; Hui KY; Haber E
    Science; 1985 Aug; 229(4715):765-7. PubMed ID: 4023710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome].
    Lü CP; Yang H; Wang J; Dong XL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Nov; 37(11):1035-8. PubMed ID: 20137334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An antifibrin monoclonal antibody useful in immunoscintigraphic detection of thrombi.
    Wasser MN; Koppert PW; Arndt JW; Emeis JJ; Feitsma RI; Pauwels EK; Nieuwenhuizen W
    Blood; 1989 Aug; 74(2):708-14. PubMed ID: 2665852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of monoclonal antibodies in the diagnosis of fibrinolysis].
    Wojta J; Korninger C; Kirchheimer J; Hattey E; Turcu L; Binder BR
    Wien Klin Wochenschr; 1985 Mar; 97(5):244-8. PubMed ID: 4039506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.